Figure S3


A
No prior targeted therapy
B
Prior targeted therapy
Alteration
TP53−MutOrDel
EGFR−Mutation
MCL1−Gain
EGFR−Gain
CDKN2A−MutOrDel
KRAS−Mutation
MYC−Gain
NKX2−1−Gain
ARID1A−Mutation
PKHD1−Mutation
PIK3CA−Mutation
SMARCA4−MutOrDel
PTPRD−MutOrDel
ALK−Fusion
MDM2−Gain
CTNNB1−Mutation
RB1−Mutation
CDK4−Gain
PTK2−Gain
ERBB2−Mutation
SETD2−Mutation
APC−MutOrDel
CDKN2B−MutOrDel
FAT1−MutOrDel
NF1−MutOrDel
TERT−Gain
IL7R−Gain
ALK−Mutation
RICTOR−Gain
TERC−Gain
MET−Gain
ROS1−Fusion
0.0
0.2
0.4
0.6
Prevalence
C
D
Actionable and selected oncogenic aberrations
TP53−MutOrDel
EGFR−Mutation
ARID1A−Mutation
CDKN2A−MutOrDel
PTPRD−MutOrDel
ALK−Fusion
CTNNB1−Mutation
CDKN2B−MutOrDel
MET−Gain
ROS1−Fusion
ALK−Mutation
PM_site
MT
PT